Bayer Biological Products Bayer HealthCare - Boliogical Products Division
                SearchSitemap 
HomeAbout UsAbout HaemophiliaFor KidsResearch & DevelopmentPress Releases 
Related Links
   Haemo-QoL Project
   Hemophilia Research Awards
   Living With Hemophilia
   More Haemophila Websites
Bayer Links
   Bayer Global
   Bayer HealthCare
   Bayer BP Global
   Bayer EU Sites
   General Conditions of Use
Privacy Statement
Imprint

© 2004 Bayer HealthCare, LLC

This website is intended for EU residents.

 

Press Releases

Printable Version

Bayer Recognizes FedEx Express for Its Role in Delivering Critical Medicine

From the Dock to the Doorstep, FedEx Express Comes Through for Lung Disease Patients

 
back to Press Releases
 (May 15, 2003)

Every month at about the same time, Joel Schumacher, a guitarist who toured with Jerry Lee Lewis, counts on a FedEx Express courier to be on time. But it is not a catalog order of new guitar picks that Joel is expecting. It is a critically important medicine called Prolastin®, Alpha-1 Proteinase Inhibitor (Human), that helps Joel, who has a debilitating lung disease called alpha-1, breathe easier.

Joel counts on the courier to be there, and the courier comes through every month. And, as a result of his dedication, the courier and his FedEx Express colleagues will be recognized by Bayer HealthCare, maker of Prolastin®, as "Corporate Partner of the Year" at the FedEx Express world headquarters in Memphis May 15.

FedEx Express has been the exclusive carrier for Prolastin® since deliveries began in October 1999.

"I admit, I've never really given the logistics behind my Prolastin® shipment much thought," says Joel, who was diagnosed with alpha-1 antitrypsin deficiency three years ago. "But I know that I get my treatment on time and appreciate everything Bayer and FedEx Express do together to make that happen."

Through the award, Bayer is expressing its gratitude for the high level of professional and personal commitment demonstrated by the FedEx Express team.

"This is more than a success story about a unique delivery system; this is a story about making a commitment to alpha-1 patients. The FedEx Express team is a reliable business partner, but what's even more important is that its team members share our passion for this patient community," said Joe Zuraw, director of Bayer DirectTM, the program through which the collaboration exists.
"Throughout the years, as FedEx has knocked on doors, asked for signatures, and delivered Prolastin®, Alpha-1 Proteinase Inhibitor (Human), they also have built relationships and become a part of the community in a positive, caring, and committed way. From dock to doorstep, the Bayer DirectTM/FedEx team delivers stellar service - for that we are grateful."

And the stellar service is beyond simply staying true to a business agreement. FedEx has made a significant investment in ensuring the drug is handled safely, as well as maintaining a highly secure environment.

"When we were approached with this opportunity by Bayer, we knew the product we were dealing with would require some customized structural and delivery changes," said Jerry Beyl, vice president of Worldwide Services at FedEx. "The team that handles Prolastin® on a day-to-day basis has been trained to ensure quality control and handle the whole process meticulously." Procedures that FedEx Express incorporates during the delivery of Prolastin® include special package handling and the ability to track the status of shipments from pickup to delivery through the FedEx network.

"The role of FedEx Express in making sure Prolastin® gets to alpha-1 patients when and where they need it, is a reflection of our expertise in delivering a full range of high-value, time-sensitive items to customers around the world through our extensive global network," Beyl said. "It also displays the ability - and flexibility - of FedEx Express in designing and implementing solutions that precisely meet our customers' needs."

Forward-Looking Statements
This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties, and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company, and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Contact:

Tricia McKernan
Bayer Biological Products
+1-(0)919/316-6316
E-mail: tricia.mckernan.b@bayer.com